Nervgen Pharma (NGEN) Common Equity (2024 - 2026)

Nervgen Pharma (NGEN) has reported Common Equity for 3 consecutive years, with $12.5 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Common Equity changed N/A year-over-year to $12.5 million in Q2 2026; TTM through Jun 2026 was $12.5 million, a N/A change from a year earlier, with the FY2025 full-year figure at $2.5 million, up 32.48% from the prior year.
• Common Equity was $12.5 million for Q2 2026 at Nervgen Pharma, up from $4.0 million in the prior quarter.
• Over five years, Common Equity peaked at $12.5 million in Q2 2026 and troughed at $1.8 million in Q4 2024.
• A 3-year average of $5.2 million and a median of $3.3 million in 2025 frame the typical range for Common Equity.
• The widest YoY moves for Common Equity: up 35.18% in 2025, down 35.18% in 2025.
• Over 3 years, Common Equity stood at $1.8 million in 2024, then surged by 35.18% to $2.5 million in 2025, then soared by 400.96% to $12.5 million in 2026.
• The last three Common Equity figures came in at $12.5 million (Q2 2026), $4.0 million (Q1 2026), and $2.5 million (Q4 2025), per Business Quant data.